TY - JOUR
T1 - Changes in Impaired Fasting Glucose and Borderline High Low-Density Lipoprotein-Cholesterol Status Alter the Risk of Cardiovascular Disease
T2 - A 9-Year Prospective Cohort Study
AU - Wang, Xianxuan
AU - Zhou, Yan-Feng
AU - Huang, Zegui
AU - Yu, Xinran
AU - Chen, Zekai
AU - Cai, Zefeng
AU - Lan, Yulong
AU - Li, Werijian
AU - Cai, Zhiwei
AU - Fang, Wei
AU - Chen, Guanzhi
AU - Wu, Weiqiang
AU - Wu, Shouling
AU - Chen, Youren
PY - 2022/6/21
Y1 - 2022/6/21
N2 - BackgroundWe aimed to characterize the relationships of the changes in impaired fasting glucose (IFG) and borderline high low-density lipoprotein-cholesterol (LDL-C) status with cardiovascular disease (CVD). MethodsA total of 36,537 participants who did not have previous CVD, diabetes mellitus, or high LDL-C (>= 4.1 mmol/L), nor were taking lipid-lowering drugs were recruited from the Kailuan study. The participants were allocated to six groups according to their baseline and follow-up fasting blood glucose (FBG) and LDL-C concentrations: (1) both were normal; (2) both normal at baseline, one abnormality subsequently; (3) both normal at baseline, both abnormal subsequently; (4) at least one abnormality that became normal; (5) at least one abnormality at baseline, a single abnormality subsequently; and (6) at least one abnormality, two abnormalities subsequently. The outcomes were CVD and subtypes of CVD (myocardial infarction and stroke). Multiple Cox regression models were used to calculate adjusted hazard ratio (HR) and confidence interval (95% CI). ResultsDuring a median follow-up period of 9.00 years, 1,753 participants experienced a CVD event. After adjustment for covariates, participants with IFG in combination with a borderline high LDL-C status at baseline and follow-up had higher risks of CVD (HR: 1.52; 95% CI: 1.04-2.23 and HR: 1.38, 95% CI: 1.13-1.70, respectively) compared with those with normal fasting blood glucose and LDL-C. Compared with participants that remained normal, those who changed from normality to having two abnormalities were at a higher risk of CVD (HR: 1.26; 95% CI: 0.98-1.61), as were those who changed from at least one abnormality to two abnormalities (HR: 1.48, 95% CI: 1.02-2.15). ConclusionChanges in IFG and borderline high LDL-C status alter the risk of CVD and its subtype, implying that it is important to focus on such individuals for the prevention and control of CVD.
AB - BackgroundWe aimed to characterize the relationships of the changes in impaired fasting glucose (IFG) and borderline high low-density lipoprotein-cholesterol (LDL-C) status with cardiovascular disease (CVD). MethodsA total of 36,537 participants who did not have previous CVD, diabetes mellitus, or high LDL-C (>= 4.1 mmol/L), nor were taking lipid-lowering drugs were recruited from the Kailuan study. The participants were allocated to six groups according to their baseline and follow-up fasting blood glucose (FBG) and LDL-C concentrations: (1) both were normal; (2) both normal at baseline, one abnormality subsequently; (3) both normal at baseline, both abnormal subsequently; (4) at least one abnormality that became normal; (5) at least one abnormality at baseline, a single abnormality subsequently; and (6) at least one abnormality, two abnormalities subsequently. The outcomes were CVD and subtypes of CVD (myocardial infarction and stroke). Multiple Cox regression models were used to calculate adjusted hazard ratio (HR) and confidence interval (95% CI). ResultsDuring a median follow-up period of 9.00 years, 1,753 participants experienced a CVD event. After adjustment for covariates, participants with IFG in combination with a borderline high LDL-C status at baseline and follow-up had higher risks of CVD (HR: 1.52; 95% CI: 1.04-2.23 and HR: 1.38, 95% CI: 1.13-1.70, respectively) compared with those with normal fasting blood glucose and LDL-C. Compared with participants that remained normal, those who changed from normality to having two abnormalities were at a higher risk of CVD (HR: 1.26; 95% CI: 0.98-1.61), as were those who changed from at least one abnormality to two abnormalities (HR: 1.48, 95% CI: 1.02-2.15). ConclusionChanges in IFG and borderline high LDL-C status alter the risk of CVD and its subtype, implying that it is important to focus on such individuals for the prevention and control of CVD.
KW - impaired fasting glucose
KW - borderline high low-density lipoprotein-cholesterol
KW - cardiovascular disease
KW - dynamic changes
KW - cohort study
KW - METABOLIC SYNDROME
KW - HEMORRHAGIC STROKE
KW - PREDICTIVE VALUES
KW - ASSOCIATION
KW - HEALTH
KW - MORTALITY
KW - TYPE-1
KW - SERUM
KW - ONSET
KW - AGE
U2 - 10.3389/fcvm.2022.882984
DO - 10.3389/fcvm.2022.882984
M3 - Article
SN - 2297-055X
VL - 9
JO - Frontiers in cardiovascular medicine
JF - Frontiers in cardiovascular medicine
M1 - 882984
ER -